Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
9.25
+0.40 (4.52%)
Nov 6, 2026, 4:00 PM EST - Market closed
Q32 Bio Revenue
In the year 2025, Q32 Bio had annual revenue of $53.74M. That makes Q32 Bio the 27,464th largest company in the world by revenue and 3,724th in the United States.
Revenue (ttm)
$53.74M
Revenue Growth
n/a
P/S Ratio
5.15
Revenue / Employee
$2,149,480
Employees
25
Market Cap
276.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.74M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 116.93M |
| Century Therapeutics | 109.16M |
| vTv Therapeutics | 36.84M |
| Arcturus Therapeutics Holdings | 29.37M |
| Ocugen | 4.78M |
| SAB Biotherapeutics | 114.70K |
| Inhibikase Therapeutics | 1.00 |
QTTB News
- 4 days ago - Q32 Bio Earnings release: Q3 2026 - Filings
- 4 days ago - Q32 Bio Quarterly report: Q3 2026 - Filings
- 4 days ago - Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 5 days ago - Q32 Bio Slides: Corporate presentation - Filings
- 23 days ago - Q32 Bio management to meet with Cantor Fitzgerald - TheFly
- 27 days ago - Q32 Bio initiated with an Outperform at Leerink - TheFly
- 5 weeks ago - Q32 Bio Inc trading resumes - TheFly
- 5 weeks ago - Q32 Bio Inc trading halted, volatility trading pause - TheFly